Hyperprolactinemia in patients with chronic kidney disease

  • І.О. Dudar SI “Institute of Nephrology NAMS of Ukraine” https://orcid.org/0000-0002-4372-8240
  • V.M. Savchuk SI “Institute of Nephrology NAMS of Ukraine”
  • О.М. Loboda SI “Institute of Nephrology NAMS of Ukraine”
  • E.K. Krasiuk SI “Institute of Nephrology NAMS of Ukraine”
DOI: https://doi.org/10.31450/ukrjnd.1(69).2021.09
Keywords: hyperprolactinemia, prolactin, chronic kidney disease.

Abstract

Despite rapid progress in improving dialysis technology in recent years, mortality in hemodialysis (HD) patients remains quite high. The main reasons are cardiovascular disease. The search of factors that are associated with an increased risk of adverse clinical events in patients with chronic kidney disease (CKD) is an urgent problem of modern nephrology.

Prolactin (PL) is a unique hormone that can perform the functions of both a hormone and a neuropeptide. Among patients with CKD, the frequency of hyperprolactinemia (HPL) increases with decreasing glomerular filtration rate (GFR). There is a moderate HPL due to impaired degradation of PL in the kidneys. Hemodialysis does not affect the level of PL. A negative correlation between the levels of PL and GFR, PL and albumin levels and PL and Hb levels are shown in the studies. Serum PL is positively correlated with blood pressure and the risk of cardiovascular events.

Despite the relatively high prevalence of HPL in patients with CKD, particularly in the dialysis population, there is uncertainty about the consequences of this condition for this cohort of patients. Further studies are needed to study the effects of HPL on clinical outcomes in patients with CKD. If a causal relationship between HPL and clinical outcomes, in particular cardiovascular events, is shown, HPL may be a potential target for therapeutic interventions.

Downloads

Download data is not yet available.

References

Racki S, Zaputović L, Vujicić B. et al. Cardiovascular risk factors and diseases strongly predict hemodialysis treatment outcome in maintenance hemodialysis patients. Croat Med J. 2006;46(6):936-41. PMID: 16342347.

Haring R, Friedrich N, Völzke H. et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J. 2014;35(18):1215-21. doi: 10.1093/eurheartj/ehs233.

Dourado M, Cavalcanti F, Vilar L, Cantilino A. Relationship between Prolactin, Chronic Kidney Disease, and Cardiovascular Risk. Int J Endocrinol. 2020;2020:9524839. doi: 10.1155/2020/9524839.

Lakshmi D, Meera SK, Mahesh E. Serum Prolactin Level and Inflammation in Chronic Kidney Disease. International Journal of Biochemistry Research & Review. 2016;14(1):1-9. doi: 10.9734/IJBCRR/2016/29218.

Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50(5):846-52. doi: 10.1210/jcem-50-5-846.

Carrero JJ, Kyriazis J, Sonmez A. et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7(2):207-215. doi: 10.2215/CJN.06840711.

Ataya K, Mercado A, Kartaginer J. et al. Moghissi, Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia, Fertility and Sterility, 1988;50(6):876-881. doi: https://doi.org/10.1016/S0015-0282(16)60365-5.

Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. doi: 10.1210/jc.2010-1692.

Chopra S, Verghese PP, Jacob JJ. Bromocriptine as a new therapeutic agent for peripartum cardiomyopathy. Indian J Endocrinol Metab. 2012;16(Suppl1):60-2. doi: 10.4103/2230-8210.94261.

Teichman PDV, de Oliveira GZ, Silveira SSE. et al. P0838 Hyperprolactinemia in CKD patients and its association with strenght, sexual dysfunction ans quality of life. Nephrology Dialysis Transplantation. 2020;35(Suppl. 3): gfaa142.P0838. doi: https://doi.org/10.1093/ndt/gfaa142.P0838.

Haglund F, Lu M, Vukojević V. et al. Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations. PLoS One. 2012;7(5):e36448. doi: 10.1371/journal.pone.0036448.

Bellone G. Prolactin as a promoter of growth and differentiation of hemopoietic cells. NeuroImmune Biology. 2002;2:163–175. doi: 10.1016/s1567-7443(02)80015-1.

Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends in Endocrinology & Metabolism. 2006;17(3):110-6. doi: https://doi.org/10.1016/j.tem.2006.02.005.

Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis. 1985;6(4):245-9. doi: 10.1016/s0272-6386(85)80181-5.

Lo JC, Beck GJ, Kaysen GA. et al. FHN Study. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial Int. 2017;21(2):190-196. doi: 10.1111/hdi.12489.

Al-Kuraishy HM, Al-Gareeb AI, Awad MS, Alrifai SB. Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy. Indian J Endocrinol Metab. 2016;20(1):72-79. doi:10.4103/2230-8210.172240.

Triebel J, Clapp C, Martínez de la Escalera G, Bertsch T. Remarks on the Prolactin Hypothesis of Peripartum Cardiomyopathy. Front Endocrinol (Lausanne). 2017;8:77. doi:10.3389/fendo.2017.00077.


Abstract views: 1419
PDF Downloads: 16950
Published
2021-01-09
How to Cite
DudarІ., Savchuk, V., LobodaО., & Krasiuk, E. (2021). Hyperprolactinemia in patients with chronic kidney disease. Ukrainian Journal of Nephrology and Dialysis, (1(69), 61-66. https://doi.org/10.31450/ukrjnd.1(69).2021.09
Issue
No 1(69) (2021): Ukrainian Journal of Nephrology and Dialysis
Section
Nephrology School